How to buy Mersana Therapeutics stock

Mersana Therapeutics, Inc is a biotechnology business based in the US. Mersana Therapeutics shares (MRSN) are listed on the NASDAQ and all prices are listed in US Dollars. Mersana Therapeutics employs 110 staff and has a trailing 12-month revenue of around 0.00.

Mersana Therapeutics share price

Use our graph to track the performance of MRSN stocks over time.

Mersana Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$7.66 - $29.09
50-day moving average	$17.01
200-day moving average	$20.46
Wall St. target price	$26.80
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.12

Buy Mersana Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Mersana Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Mersana Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Mersana Therapeutics financials

Revenue TTM	$828,000
Gross profit TTM	$-66,208,000
Return on assets TTM	-28.91%
Return on equity TTM	-57.47%
Profit margin	0%
Book value	$3.31
Market capitalisation	$1.1 billion

TTM: trailing 12 months

Shorting Mersana Therapeutics shares

There are currently 9.8 million Mersana Therapeutics shares held short by investors – that's known as Mersana Therapeutics's "short interest". This figure is 13.8% up from 8.6 million last month.

There are a few different ways that this level of interest in shorting Mersana Therapeutics shares can be evaluated.

Mersana Therapeutics's "short interest ratio" (SIR)

Mersana Therapeutics's "short interest ratio" (SIR) is the quantity of Mersana Therapeutics shares currently shorted divided by the average quantity of Mersana Therapeutics shares traded daily (recently around 792423.50565428). Mersana Therapeutics's SIR currently stands at 12.38. In other words for every 100,000 Mersana Therapeutics shares traded daily on the market, roughly 12380 shares are currently held short.

However Mersana Therapeutics's short interest can also be evaluated against the total number of Mersana Therapeutics shares, or, against the total number of tradable Mersana Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Mersana Therapeutics's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Mersana Therapeutics shares in existence, roughly 140 shares are currently held short) or 0.1767% of the tradable shares (for every 100,000 tradable Mersana Therapeutics shares, roughly 177 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Mersana Therapeutics.

Find out more about how you can short Mersana Therapeutics stock.

Mersana Therapeutics share dividends

We're not expecting Mersana Therapeutics to pay a dividend over the next 12 months.

Mersana Therapeutics share price volatility

Over the last 12 months, Mersana Therapeutics's shares have ranged in value from as little as $7.66 up to $29.09. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mersana Therapeutics's is 2.4825. This would suggest that Mersana Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Mersana Therapeutics overview

Mersana Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc.

Frequently asked questions

• What percentage of Mersana Therapeutics is owned by insiders or institutions?

  Currently 1.267% of Mersana Therapeutics shares are held by insiders and 102.201% by institutions.

• How many people work for Mersana Therapeutics?

  Latest data suggests 110 work at Mersana Therapeutics.

• When does the fiscal year end for Mersana Therapeutics?

  Mersana Therapeutics's fiscal year ends in December.

• Where is Mersana Therapeutics based?

  Mersana Therapeutics's address is: 840 Memorial Drive, Cambridge, MA, United States, 02139

• What is Mersana Therapeutics's ISIN number?

  Mersana Therapeutics's international securities identification number is: US59045L1061

• What is Mersana Therapeutics's CUSIP number?

  Mersana Therapeutics's Committee on Uniform Securities Identification Procedures number is: 59045L106